Oorsprong van het eerstegraads netwerk van Jean-Pierre Grootaers
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Medinvents NV
Medinvents NV Medical SpecialtiesHealth Technology Medinvents NV engages in the manufacture of biopsy surgical instruments. The company was founded on December 28, 1992 and is headquartered in Hasselt, Belgium.
3
| Private Company | Medical Specialties | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Jean-Pierre Grootaers via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
SEPS Pharma NV
SEPS Pharma NV Pharmaceuticals: GenericHealth Technology SEPS Pharma NV provides controlled drug delivery and develops self emulsifying pro drug systems. Its services include preformulation, formulation development and analytical development. The company was founded on October 19, 2007 and is headquartered in Diepenbeek, Belgium. | Pharmaceuticals: Generic | Director/Board Member | |
Ghent University | College/University | Doctorate Degree | |
JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal | |
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Miscellaneous Commercial Services | Director/Board Member | |
Hasselt University | College/University | Doctorate Degree | |
Life Sciences Consultancy | Founder | ||
TIGENIX NV | Medical Specialties | Public Communications Contact | |
Life Sciences Development Campus NV
Life Sciences Development Campus NV Miscellaneous Commercial ServicesCommercial Services Life Sciences Development Campus NV provides research and development services in the field of biomedical life sciences. The company is headquartered in Abis, BelGium. | Miscellaneous Commercial Services | Chief Executive Officer |
Statistieken
Internationaal
België | 6 |
Verenigde Staten | 3 |
Verenigd Koninkrijk | 3 |
Nederland | 2 |
Sectoraal
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 3 |
Finance | 2 |
Operationeel
Director/Board Member | 7 |
Doctorate Degree | 2 |
Founder | 2 |
Chief Executive Officer | 2 |
Corporate Officer/Principal | 1 |
Sterkste connecties
Insiders | |
---|---|
Kris Motmans | 12 |
Magda Buttiens | 1 |
Johan Janssens | 1 |
- Beurs
- Insiders
- Jean-Pierre Grootaers
- Bedrijfsconnecties